Search
New Study Finds Significant Impact of Plant-Based Diets on CKD Patients
(December 14, 2023 – New York, NY) – A study published in this month's issue of the National Kidney Foundation American Journal of Kidney Diseases (AJKD) provides new insights into the role of diet in the management of...
(April 14, 2022, AUSTIN, TX) —The main results of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) trial, a National Heart, Lung, and Blood Institute (NHLBI) sponsored trial were presented. Although the results of the trial are not final, they offer valuable information for patients using the generic drug Spironolactone. This drug therapy activates white cells and...
(April 12, 2023, New York, NY) — The National Kidney Foundation (NKF) will feature a late-breaking plenary session by Travere Therapeutics on the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) in adults with IgA nephropathy (IgAN). “Rapid and Sustained Proteinuria Reduction with Sparsentan in Immunoglobulin A Nephropathy (IgAN): PROTECT Study Interim Results...
March 31, 2022, New York, NY — Researchers will present at the National Kidney Foundation’s Spring Clinical Meetings the results of a clinical trial of a new therapy that gives hope to people with a specific genetic mutation that can cause kidney damage.
APOL1-mediated kidney disease (AMKD) is a serious disease caused by mutations in the APOL1 gene that lead to damage in certain...
Award-winning actress and NKF’s chief medical officer take their message directly to the American Academy of Family Physicians
Sept. 30, 2021, New York, NY — Family doctors and primary care practices need to ramp up kidney disease testing, using both a blood and...
August 31, 2021, New York, NY— The National Kidney Foundation (NKF) in partnership with the NephCure Kidney International, Inc. (NephCure) hosted a gathering of patients and care partners to share with the U.S. Food and Drug Administration (FDA) their experience with a rare kidney disease, membranous nephropathy...
Authors studied lab results for 28 million Americans with the highest risk and found most are not getting recommended tests to detect life-threatening disease
August 5, 2021, New York, NY — New data suggest that millions of patients most at-risk for life-threatening kidney disease are unaware they have it because they are not tested according to clinical practice guidelines despite their risk. The study, by authors from the National...
Dec. 7, 2020, New York, NY —A new study published today in the National Kidney Foundation’s American Journal of Kidney Diseases (AJKD) has found that it is possible to accurately assess patients for the stages of kidney disease without using race in the equation, which is currently routinely used as part of the diagnosis process in the United States.
Kidney disease affects an...
Initiative Marks New Phase of the NKF “Are You the 33%?” National Kidney Disease Awareness Campaign
Whippany, N.J., – (BUSINESS WIRE) – February 4, 2021 – Bayer and the National Kidney Foundation (NKF) today announced that award-winning actress, Debbie Allen, has joined the “Are You the 33%?” national public awareness campaign to focus attention on the increased risk of developing chronic kidney disease (CKD), also referred to as...